These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31537509)

  • 21. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
    Hézode C; Chevaliez S; Scoazec G; Soulier A; Varaut A; Bouvier-Alias M; Ruiz I; Roudot-Thoraval F; Mallat A; Féray C; Pawlotsky JM
    Hepatology; 2016 Jun; 63(6):1809-16. PubMed ID: 26853230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
    Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
    J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C: efficacy and safety in real life.
    Flisiak R; Pogorzelska J; Flisiak-Jackiewicz M
    Liver Int; 2017 Jan; 37 Suppl 1():26-32. PubMed ID: 28052633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil.
    Holzmann I; Tovo CV; Minmé R; Leal MP; Kliemann MP; Ubirajara C; Aquino AA; Araujo B; Almeida PRL
    Braz J Infect Dis; 2018; 22(4):317-322. PubMed ID: 30036490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
    Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
    Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
    Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
    BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
    Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
    J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
    PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
    Pott-Junior H; Bricks G; Grandi G; Figueiredo Senise J; Castelo Filho A
    Clin Microbiol Infect; 2019 Mar; 25(3):365-371. PubMed ID: 29906601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    Darvishian M; Wong S; Binka M; Yu A; Ramji A; Yoshida EM; Wong J; Rossi C; Butt ZA; Bartlett S; Pearce ME; Samji H; Cook D; Alvarez M; Chong M; Tyndall M; Krajden M; Janjua NZ
    J Viral Hepat; 2020 Mar; 27(3):243-260. PubMed ID: 31664755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
    Sinakos E; Kountouras D; Koskinas J; Zachou K; Karatapanis S; Triantos C; Vassiliadis T; Goulis I; Kourakli A; Vlachaki E; Toli B; Tampaki M; Arvaniti P; Tsiaoussis G; Bellou A; Kattamis A; Maragkos K; Petropoulou F; Dalekos GN; Akriviadis E; Papatheodoridis GV
    Br J Haematol; 2017 Jul; 178(1):130-136. PubMed ID: 28439915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
    Calvaruso V; Mazzarelli C; Milazzo L; Badia L; Pasulo L; Guaraldi G; Lionetti R; Villa E; Borghi V; Carrai P; Alberti A; Biolato M; Piai G; Persico M; Santantonio T; Felder M; Angelico M; Montalbano M; Mancusi RL; Grieco A; Angeli E; D'Offizi G; Fagiuoli S; Belli L; Verucchi G; Puoti M; Craxì A
    Sci Rep; 2019 Jan; 9(1):585. PubMed ID: 30679515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    Fathi H; Clark A; Hill NR; Dusheiko G
    BMC Infect Dis; 2017 Nov; 17(1):722. PubMed ID: 29145802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.